Shots:

• The approval is based on P-III trial evaluating efficacy & safety of Kyprolis + dexamethasone in 123 patients with RRMM who have received at least 2 prior therapies- including a proteasome inhibitor & an immunomodulatory agent
• Results: ORR (35.8%); m-PFS (5.6mos.) as assessed by IRC. Additionally- results showed that the efficacy & safety in Chinese patients who had received a median of 4 prior lines of therapy was generally consistent with that seen in the global studies
• BeiGene got the license for Kyprolis under its collaboration with Amgen. The approval marks the first approval of the therapy in China

  Ref: BeiGene | Image: Forbes